Microbot Medical Inc. (MBOT) is a commercial-stage medical device company based in Hingham, Massachusetts, best known for its LIBERTY Endovascular Robotic System, the first single-use, remotely operated robotic platform cleared by the U.S. Food and Drug Administration (FDA) for peripheral endovascular procedures. After a sharp pullback from its 2025 highs, the stock now trades near $1.09, leaving investors asking a simple but consequential question: can it climb back toward a $5.40 stock price target?
Four current, attributable analyst targets were reviewed to calculate the central figure. H.C. Wainwright reiterated a Buy rating with a $12.00 target in late October 2026, while Citizens JMP initiated coverage at $2.50. Lucid Capital lowered its target to $3.00 from $4.00 in late September 2026, and B. Riley Securities maintained a Buy at $4.00. The arithmetic mean of these four figures is about $5.38, rounded to a $5.40 average analyst price target, with a range of $2.50 to $12.00.
The spread matters. The $12.00 target — the highest — reflects a more aggressive view of LIBERTY's commercial ramp and international expansion, whereas the $2.50-to-$4.00 cluster reflects more conservative modeling of a very early-stage revenue story. Because the high target pulls the average upward, the mean is meaningfully above the midpoint of the range, and investors should read it as a statistical center rather than a guarantee.
With shares near $1.09 and a market capitalization around $75 million, MBOT sits far below its 52-week high and well under the $5.40 target. Reaching that level would require a move of roughly 395% — a very large gain that would effectively require the market to re-rate the company from a speculative micro-cap into a credible growth story with demonstrated commercial traction.
The path would likely depend on sustained revenue acceleration, not just product clearance. LIBERTY received FDA 510(k) clearance in September 2025, completed a limited market release, and transitioned to full market release in April 2026. Adoption by systems such as Emory Healthcare and Tampa General Hospital provides early validation, but reported revenue remains minimal, and management does not expect positive gross margins until 2027.
MBOT has traded within a broad 52-week range, with support near its 52-week low around $0.93 and a 52-week high near $2.86. The $1.00 level is a psychological support zone, while any move toward the target would first need to reclaim the $2.00 area and then the 52-week high, each representing meaningful overhead resistance. With a small float and frequent double-digit percentage daily swings, the stock's technical structure favors sharp, liquidity-driven moves in both directions.
Analyst price targets typically reflect a roughly 12-month horizon, though the wide range here signals materially different assumptions about the timing of commercial adoption. Key items to watch include quarterly revenue progression, the number of active hospital accounts and repeat usage, progress toward positive gross margins in 2027, the anticipated CE mark decision, and any analyst target revisions following earnings. Given the company's Israel-based operations, any escalation of regional geopolitical tensions is also worth monitoring.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like MBOT, this kind of systematic scanning can help traders spot emerging trends and monitor positions more efficiently than manual chart review alone. Traders looking for a more disciplined way to identify opportunities may find the platform a useful complement to fundamental research.
The $5.40 target represents the average of four analyst price targets, a figure distorted upward by the $12.00 high estimate from H.C. Wainwright. From roughly $1.09, reaching it would require a very large gain of about 395% — a move that hinges almost entirely on LIBERTY's commercial execution, revenue acceleration, and successful international expansion. The differentiated, FDA-cleared product and strong balance sheet are genuine strengths, but minimal current revenue, persistent losses, and a contested bearish thesis are serious obstacles. The most likely near-term path involves volatile, sentiment-driven trading rather than a smooth advance, and investors should weigh the wide analyst range as evidence of genuine uncertainty rather than consensus conviction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with AGPU. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then AGPU could also see price increases.
| Ticker / NAME | Correlation To MBOT | 1D Price Change % | ||
|---|---|---|---|---|
| MBOT | 100% | -2.68% | ||
| AGPU - MBOT | 37% Loosely correlated | -8.78% | ||
| QSI - MBOT | 33% Poorly correlated | -16.57% | ||
| AIMD - MBOT | 32% Poorly correlated | -15.76% | ||
| CODX - MBOT | 31% Poorly correlated | -7.16% | ||
| BWAY - MBOT | 30% Poorly correlated | -4.78% | ||
More | ||||
| Ticker / NAME | Correlation To MBOT | 1D Price Change % |
|---|---|---|
| MBOT | 100% | -2.68% |
| Medical/Nursing Services industry (138 stocks) | 5% Poorly correlated | -1.17% |
| Health Services industry (239 stocks) | 4% Poorly correlated | -1.35% |